Roche provides update on US FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory ...
Roche announced that a US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussed the supplemental Biologics License Application (sBLA) for Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the …